

Roser Pinyol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2532752/publications.pdf>

Version: 2024-02-01

31
papers

5,001
citations

236925

25
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

7345
citing authors

#	ARTICLE	IF	CITATIONS
1	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	12.1	90
2	Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2449-2460.	7.0	39
3	CXCR2 inhibition enables NASH-HCC immunotherapy. <i>Gut</i> , 2022, 71, 2093-2106.	12.1	66
4	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	13.2	126
5	Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. <i>Molecular Therapy</i> , 2021, 29, 680-690.	8.2	61
6	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
7	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 865-878.	3.7	111
8	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6350-6361.	7.0	35
9	Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, S40.	3.7	7
10	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 73, 315-327.	3.7	164
11	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019, 68, 1065-1075.	12.1	195
12	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. <i>British Journal of Cancer</i> , 2019, 121, 340-343.	6.4	62
13	An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. <i>Gastroenterology</i> , 2019, 157, 1383-1397.e11.	1.3	62
14	Ras-Responsive Kinase 2 Drives Liver Tumor Development in a Yes-Associated Protein-Dependent Manner. <i>Hepatology Communications</i> , 2019, 3, 1496-1509.	4.3	15
15	Platelet GPIb-IX-V is a mediator and potential interventional target for NASH and subsequent liver cancer. <i>Nature Medicine</i> , 2019, 25, 641-655.	30.7	259
16	Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC. <i>Clinical Cancer Research</i> , 2019, 25, 2021-2023.	7.0	152
17	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. <i>Gastroenterology</i> , 2016, 151, 1192-1205.	1.3	103
18	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	12.8	240

#	ARTICLE	IF	CITATIONS
19	DNA methylation-based prognosis and epdrivers in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	7.3	367
20	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	21.4	1,372
21	Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. <i>Seminars in Liver Disease</i> , 2014, 34, 363-375.	3.6	47
22	Genome-scale metabolic models for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 336-337.	17.8	19
23	Integration of genomic information in the clinical management of HCC. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 831-842.	2.4	19
24	TERT promoter mutations: Gatekeeper and driver of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 685-687.	3.7	40
25	The Role of NEDD1 Phosphorylation by Aurora A in Chromosomal Microtubule Nucleation and Spindle Function. <i>Current Biology</i> , 2013, 23, 143-149.	3.9	53
26	Nek9 Phosphorylation of NEDD1/GCP-WD Contributes to Plk1 Control of β -Tubulin Recruitment to the Mitotic Centrosome. <i>Current Biology</i> , 2012, 22, 1516-1523.	3.9	67
27	F-BAR Proteins of the Syndapin Family Shape the Plasma Membrane and Are Crucial for Neuromorphogenesis. <i>Journal of Neuroscience</i> , 2009, 29, 13315-13327.	3.6	103
28	Cordon-Bleu Is an Actin Nucleation Factor and Controls Neuronal Morphology. <i>Cell</i> , 2007, 131, 337-350.	28.9	227
29	Regulation of N-WASP and the Arp2/3 Complex by Abp1 Controls Neuronal Morphology. <i>PLoS ONE</i> , 2007, 2, e400.	2.5	85
30	Capillary electrophoresis method for the enzymatic assay of galactosyltransferases with postreaction derivatization. <i>Analytical Biochemistry</i> , 2005, 346, 115-123.	2.4	11
31	EHD Proteins Associate with Syndapin I and II and Such Interactions Play a Crucial Role in Endosomal Recycling. <i>Molecular Biology of the Cell</i> , 2005, 16, 3642-3658.	2.1	143